Bioscience

Radient Pharmaceutical buying Provista Diagnostics

July 13, 2010

By Flinn Foundation

[Source: Phoenix Busines Journal] – Provista Diagnostics Inc., a Phoenix biotech company marketing blood tests for breast cancer and other diseases, has signed a letter of intent to be acquired by Radient Pharmaceutical Corp. of California

Radient announced today its intent to acquire Provista in a stock-for-stock transaction. Provista has rights, patents and trademarks for diagnostic technologies that Radient believes will strengthen and complement its core business.

For more information: Radient Pharmaceutical buying Provista Diagnostics